Search results for "tips"

showing 10 items of 280 documents

Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.

2008

Abstract Because of a unique pharmacodynamic profile, amisulpride seems appropriate for treatment of elderly patients with schizophrenia. In a large-scale naturalistic therapeutic drug monitoring study, daily amisulpride dose, trough and dose-corrected amisulpride plasma levels, co-medication, clinical effectiveness (CGI) and side effects (UKU) were compared between age groups in 395 patients with schizophrenia or schizoaffective disorder (46% women; mean age 39.1 ± 14.2 years, range 18–83 years) under amisulpride therapy. Mean amisulpride doses (574 ± 269 mg/day), plasma levels (304 ± 274 ng/mL), dose-corrected amisulpride plasma levels (C/D ratios, 0.52 ± 0.41 ng/mL:mg), clinical respons…

AdultMalemedicine.medical_specialtySide effectAdolescentmedicine.drug_classPoison controlAtypical antipsychoticSchizoaffective disorderComorbidityGastroenterologyYoung AdultExtrapyramidal symptomsInternal medicinemedicineHumansPharmacology (medical)AmisulpridePsychiatryAgedPharmacologyAged 80 and overDose-Response Relationship DrugDopamine antagonistAge FactorsMiddle Agedmedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaFemalemedicine.symptomAmisulprideDrug MonitoringSulpiridePsychologymedicine.drugAntipsychotic AgentsJournal of psychopharmacology (Oxford, England)
researchProduct

Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.

2006

INTRODUCTION: It is assumed that female and male schizophrenic patients respond differentially to acute and chronic treatment with antipsychotics because of pharmacokinetic and pharmacodynamic factors linked to hormonal and constitutional gender differences. However, to date no empirical evidence exists in support of this notion. METHODS: In a naturalistic clinical study, we investigated gender differences in a sample of schizophrenic inpatients with acute exacerbation treated with the atypical antipsychotic amisulpride, a selective dopamine D2/D3 receptor antagonist with proven antipsychotic efficacy. Prescribed amisulpride dose, plasma level, clinical response (CGI), and side effects (UKU…

AdultMalemedicine.medical_specialtySide effectExacerbationmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticPharmacologyDrug Administration ScheduleSex FactorsInternal medicinemedicineHumansPharmacology (medical)AmisulprideAntipsychoticmedicine.diagnostic_testGeneral MedicineDrug ToleranceHospitalizationPsychiatry and Mental healthTherapeutic drug monitoringPharmacodynamicsSchizophreniaFemaleAmisulprideDrug MonitoringSulpiridePsychologySulpiridemedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

Predicting relapse after a first episode of non-affective psychosis: A three-year follow-up study

2011

Preventing relapse during the first years of illness has a critical impact on lifelong outcomes in schizophrenia. A better understanding and improvement in factors which influence relapse should diminish the risk of relapse and consequently improve the outcome of the illness.To identify factors associated with relapse after 3 years of a first episode in a sample of non-affective psychosis patients who are representative of clinical practice in an epidemiological catchment.We analyzed socio-demographic and clinical data from a cohort of patients who were treated in a specialized early intervention service and who were at risk of relapse during a 3-year follow-up. Univariate analyses, logisti…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentYoung AdultCatchment Area HealthPredictive Value of TestsInternal medicineEpidemiologySecondary PreventionmedicineHumansLongitudinal StudiesFamily historyPsychiatryBiological PsychiatryProportional Hazards ModelsRetrospective StudiesPsychiatric Status Rating ScalesFirst episodeUnivariate analysisProportional hazards modelHazard ratioRetrospective cohort studyMiddle AgedSurvival AnalysisPsychiatry and Mental healthLogistic ModelsPsychotic DisordersCohortFemalePsychologyAntipsychotic AgentsJournal of Psychiatric Research
researchProduct

Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients

2010

To describe the course of positive and negative symptoms during inpatient treatment and examine remission and response rates under routine clinical care conditions.Two hundred and eighty inpatients with schizophrenia (DSM-IV criteria) were assessed with the Positive and Negative Syndrome Scale (PANSS) at admission and at biweekly intervals until discharge from hospital. Remission was defined according to the symptom-severity component of the consensus criteria (Remission in Schizophrenia Working Group) as a rating of three or less in the relevant PANSS items at discharge, and response as a reduction of at least 20% in the PANSS total score from admission to discharge.The mean duration of in…

AdultMalemedicine.medical_specialtyTime FactorsAntipsychotic treatmentSeverity of Illness IndexYoung Adult03 medical and health sciences0302 clinical medicineNaturalistic observationInternal medicineOutcome Assessment Health CareSeverity of illnessmedicineHumansYoung adultPsychiatryBiological PsychiatryRetrospective StudiesPsychiatric Status Rating ScalesPositive and Negative Syndrome ScaleRetrospective cohort studyMiddle Agedmedicine.disease030227 psychiatry3. Good healthDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthSchizophreniaTime courseSchizophreniaRegression AnalysisFemalePsychology030217 neurology & neurosurgeryAntipsychotic AgentsSchizophrenia Research
researchProduct

Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels

2002

In the present study, we investigated the long-term effects of treatment with amisulpride, a substituted benzamide derivative, as compared with the effects of treatment with flupenthixol, a thioxanthene, on the prolactin levels in schizophrenic patients. After completing 6 weeks of medication with either amisulpride or flupenthixol, the patients entered a long-term maintenance treatment with amisulpride 200–600 mg/day or flupenthixol 5–15 mg/day for a maximum of 12 months with a subsequent drug-free follow-up until month 15. Eighteen initially included patients were still participating in the study at month 6. In the flupenthixol group, only 1 patient treated reached month 12, and none of t…

AdultMalemedicine.medical_specialtyTime FactorsThyrotropin-releasing hormoneFlupenthixolDrug Administration Schedulelaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicinemedicineHumansAmisulprideBenzamideThyrotropin-Releasing HormoneBiological PsychiatryMiddle AgedProlactinProlactinFlupentixolFlupenthixolPsychiatry and Mental healthNeuropsychology and Physiological PsychologyEndocrinologychemistrySchizophreniaFemaleAmisulprideSulpiridePsychologyAntipsychotic Agentsmedicine.drugHormoneNeuropsychobiology
researchProduct

Predictors of Re‐bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic S…

2018

Abstract Background Transjugular intrahepatic portosystemic shunt (TIPS) has proven clinical efcacy as rescue therapy for cirrhotic patients with acute portal hypertensive bleeding who fail endoscopic treatment. Aims To investigate predictive factors of 6-week and 1-year mortality in patients undergoing salvage TIPS for refractory portal hypertensive bleeding. Methods A total of 144 consecutive patients were retrospectively evaluated. Three logistic regression multivariate models were estimated to individualize prognostic factors for 6-week and 12-month mortality. Log-rank test was used to evaluate survival according to Child–Pugh classes and Bureau’s criteria. Results Mean age 51±10 years,…

AdultMalemedicine.medical_specialtyVariceal bleedingPhysiologymedicine.medical_treatmentPortal venous pressureEsophageal and Gastric VaricesLogistic regressionlaw.inventionCohort Studies03 medical and health sciences0302 clinical medicineRefractoryPredictive Value of TestsRecurrencelawInternal medicinemedicineHumansProspective StudiesMortalityRetrospective StudiesSalvage Therapybusiness.industryGastroenterologyMiddle AgedHepatologyIntensive care unitSurgeryRe bleeding030220 oncology & carcinogenesisTIPSFemale030211 gastroenterology & hepatologyPortasystemic Shunt Transjugular IntrahepaticGastrointestinal HemorrhagebusinessTransjugular intrahepatic portosystemic shunt
researchProduct

Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care

2017

Medication non adherence in schizophrenia is a major cause of relapse and hospitalization and remains for clinicians an important challenge. This study investigates the associations between insight, therapeutic alliance, perceived trauma related to psychiatric treatment and medication adherence in patients with schizophrenia. In this multicenter study, 72 patients were assessed regarding symptomatology, self-reported adherence with medication, insight, medication side-effects, therapeutic alliance and perceived trauma related to psychiatric treatment. Structural Equation Modeling (SEM) was used to test predicted paths among these variables. The data fit a model in which medication adherence…

AdultMalemedicine.medical_specialty[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyMedication adherencePsychological TraumaStructural equation modelingMedication Adherence[ SDV.NEU.PC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behavior03 medical and health sciences[ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences0302 clinical medicineMedicineHumansIn patientPsychiatryBiological PsychiatryComputingMilieux_MISCELLANEOUS[SDV.NEU.PC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Psychology and behaviorbusiness.industry[SCCO.NEUR]Cognitive science/Neuroscience[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesProfessional-Patient RelationsAwarenessMiddle Agedmedicine.diseaseMental healthNon adherence030227 psychiatry3. Good healthPsychiatry and Mental healthAllianceMulticenter studySchizophrenia[ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology[ SCCO.NEUR ] Cognitive science/NeuroscienceSchizophreniaFemalebusiness030217 neurology & neurosurgeryClinical psychologyAntipsychotic Agents
researchProduct

Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone p…

2018

BACKGROUND Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI. METHOD Enrolled were 143 (97 males, 46 females, mean age 38.24 years, SD = 12.65) patients with a diagnosis of schizophrenia or schizoaffective disorder, whom we allocated in two gr…

AdultMalemedicine.medical_specialtyaripiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; neurology; neurology (clinical); psychiatry and mental health; pharmacology (medical)Global Assessment of FunctioningAripiprazoleSchizoaffective disorderPharmacyOutcome Assessment (Health Care)03 medical and health sciencesYoung Adult0302 clinical medicineglobal assessment of functioningInternal medicineOutcome Assessment Health CarePaliperidone PalmitatemedicineHumansPharmacology (medical)aripiprazole monohydratearipiprazole monohydrate; global assessment of functioning; long-acting injectable antipsychotics; paliperidone palmitate; schizoaffective disorder; schizophrenia; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult; Outcome Assessment (Health Care)Paliperidone Palmitatebusiness.industrylong-acting injectable antipsychoticsMiddle Agedschizoaffective disordermedicine.disease030227 psychiatryPsychiatry and Mental healthNeurologyPsychotic DisordersSchizophreniaDelayed-Action PreparationsSettore SECS-P/03 - Scienza delle FinanzeSchizophreniaChronic schizophreniaAripiprazoleFemaleNeurology (clinical)business030217 neurology & neurosurgeryDiagnosis of schizophreniamedicine.drugAntipsychotic AgentsHuman psychopharmacology
researchProduct

Risperidone in the Treatment of Disorders with a combined Psychotic and Depressive Syndrome - A Functional Approach

1992

In vitro receptor-binding profiles and in vivo pharmacological studies have shown risperidone to be a potent mixed serotonin-S2 dopamine-D2-like receptor antagonist. While anti-D2 activity may relate to the antipsychotic potency of neuroleptic drugs, an antidepressive efficacy of substances with anti-S2 activity has been suggested. In an open pilot-study, ten patients with schizodepressive disorders or a DSM-III-R diagnosis of psychotic major depressive episodes were treated with risperidone (2-10 mg/d) for six weeks. Weekly psychopathological evaluation was performed, including BPRS, SANS, SAPS, VAS scales, and AIMS and UKU for the assessment of side-effects. Generally, the psychotic syndr…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPiperidinesInternal medicineHumansMedicinePotencyPharmacology (medical)AntipsychoticDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderRisperidonebusiness.industryDopamine antagonistIsoxazolesSyndromeGeneral MedicineMiddle AgedRisperidoneReceptor antagonistBiperidenPsychiatry and Mental healthPsychotic DisordersAnesthesiaFemalebusinessAntipsychotic AgentsPsychopathologymedicine.drugPharmacopsychiatry
researchProduct

Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.

2011

Abstract Background To examine the influencing factors and predictors of early improvement in schizophrenia patients. Methods 370 patients suffering from a schizophrenia spectrum disorder were examined within a naturalistic multicenter study. Early improvement was defined as a ≥30% PANSS total score reduction within the first two treatment weeks, response as a ≥50% improvement of the PANSS total score from admission to discharge and remission according to the consensus remission criteria. Baseline and course-related variables such as positive, negative and depressive symptoms, side effects, functioning and subjective well-being were examined regarding their explanatory value for early impro…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMedizinAntipsychotic treatment03 medical and health sciencesYoung Adult0302 clinical medicineRemission criteriaPredictive Value of TestsInternal medicinemedicineHumansPsychiatryAntipsychoticBiological PsychiatryDepressive symptomsRetrospective StudiesPsychiatric Status Rating Scalesbusiness.industryMiddle Agedmedicine.disease030227 psychiatry3. Good healthDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthTreatment OutcomeMulticenter studyROC CurveSchizophreniaSchizophreniaFemalebusiness030217 neurology & neurosurgerySchizophrenia spectrumAntipsychotic AgentsFollow-Up StudiesJournal of psychiatric research
researchProduct